16-30 of 282
Disease-Modifying Advances in ATTR-CM Management
Heart MattersDisease-Modifying Advances in ATTR-CM Management
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
AudioAbstractsIntegrating CMR and Genetics to Improve ATTR-CM Diagnosis
Ryan Quigley
Retifanlimab Across POD1UM-303 Subgroups in Squamous Cell Carcinoma of the Anal Canal
Project Oncology®Retifanlimab Across POD1UM-303 Subgroups in Squamous Cell Carcinoma of the Anal Canal
Charles Turck, PharmD, BCPS, BCCCP
Marwan G. Fakih, MD
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
On the Frontlines of ATTR-CMRNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
Shelina Ramnarine, PhD
Chadi Alraies, MD, MPH, FACC
Rethinking PBC Care: Inside the RESPONSE Trial
GI InsightsRethinking PBC Care: Inside the RESPONSE Trial
Brian P. McDonough, MD, FAAFP
Gideon Hirschfield, MB, BChir, PhD
Updates in AML Care: Evolving ASH Guidelines for Older Adults
On the Frontlines of AML/ALLUpdates in AML Care: Evolving ASH Guidelines for Older Adults
Shelina Ramnarine, PhD
Mikkael A. Sekeres, MD, MS
- advertisement
Venetoclax and Palbociclib in AML: Exploring New Findings
On the Frontlines of AML/ALLVenetoclax and Palbociclib in AML: Exploring New Findings
Ryan Quigley
Jeffrey Tyner, PhD
Melissa Stewart, PhD
Assessing Quality of Life in Autoimmune Liver Diseases
GI InsightsAssessing Quality of Life in Autoimmune Liver Diseases
Charles Turck, PharmD, BCPS, BCCCP
Alan Bonder, MD
A New Era in Primary Biliary Cholangitis Treatment
GI InsightsA New Era in Primary Biliary Cholangitis Treatment
Charles Turck, PharmD, BCPS, BCCCP
Alan Bonder, MD
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
NeuroFrontiersSpinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
NeuroFrontiersEarly ALS Patients Show Slowed Decline with Pridopidine Treatment
Switching to Risdiplam Maintains Motor Gains in SMA Patients
AudioAbstractsSwitching to Risdiplam Maintains Motor Gains in SMA Patients
Ryan Quigley
- advertisement
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
NeuroFrontiersCK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
Expanding Access to CAR T-Cell Therapy in R/R Myeloma Care
Project Oncology®Expanding Access to CAR T-Cell Therapy in R/R Myeloma Care
Brian P. McDonough, MD, FAAFP
Tara Graff, DO, MS
Surbhi Sidana, MD
Optimizing Care for Older Adults With FLT3-Mutated AML
On the Frontlines of AML/ALLOptimizing Care for Older Adults With FLT3-Mutated AML
Ryan Quigley
Nicholas Short, MD
